Changing lives through cell survival
Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide keeps more cells alive longer. It utilizes the same properties that help animals survive in arctic temperatures, and it has the capability to change regenerative medicine forever.
With AAGP®, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve.
Initial public offering
First intellectual property (IP) filing
Initial application for pipeline research
Good Manufacturing Practice processing and toxicology study success
IP second filing and Type 1 diabetes islet transplantation study
Preclinical validation in Type 1 diabetes and peer reviewed papers
IP third filing and induced pluripotent stem cells study for macular degeneration
Preclinical validation in macular degeneration
Engage Food and Drug Administration for consultation on Investigational Drugs and Devices approval for topical products
Large-scale bioproduct validation
First licensing agreement for topical products
Published phase one clinical results for Type 1 diabetes
Orphan disease status approval
Initiate phase one clinical trial for macular degeneration
Initiate phase two clinical trial for Type 1 diabetes
Milestone partnership agreement for biological biosimilar production
We are moving cell survival forward by addressing the health conditions that affect our lives. See where we are today and where we are heading next.
The leaders at ProtoKinetix have a clear vision for the future of the company and for the future of regenerative medicine. Learn more about their backgrounds.